Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Prothena Corporation plc - Ordinary Shares (NQ: PRTA )

13.86 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Prothena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Via Benzinga
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Earnings Scheduled For February 20, 2025
Via Benzinga
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Prothena Corporation plc
Via Business Wire
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Demystifying Prothena Corp: Insights From 6 Analyst Reviews
Via Benzinga
Expert Ratings For Prothena Corp
Via Benzinga
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Prothena Announces Board of Directors Update
From Prothena Corporation plc
Via Business Wire
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
The drug technically missed the study's primary goal. But there's still promise it could work in specific patients. 
Via Investor's Business Daily
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Preview For Prothena Corp
Via Benzinga
Breaking Down Prothena Corp: 4 Analysts Share Their Views
Via Benzinga
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses. 
Via Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
From Prothena Corporation plc
Via Business Wire
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Third Quarter 2024 Financial Results on November 12
From Prothena Corporation plc
Via Business Wire
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Dow Dips 300 Points; Emcore Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Prothena Announces Leadership Team Updates
From Prothena Corporation plc
Via Business Wire
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
PRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024
PRTA stock results show that Prothena Corp beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Second Quarter 2024 Financial Results on August 8
From Prothena Corporation plc
Via Business Wire
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.